Endo names Coughlin SVP, COO, adds Pera as Par president
DUBLIN — Endo on Monday announced the appointment of two key executive leadership team members, naming Terrance J. Coughlin its EVP and COO, and adding Tony Pera as the president of Endo’s U.S. generics company Par Pharmaceutical. The appointments are effective Nov. 1.
“I am excited and very pleased to add Terry and Tony to Endo's executive leadership team and to continue to strengthen the management of the company," Endo president and CEO Paul Campanelli said. “Terry has worked closely with me over the past 25 years as a partner and collaborator, most recently leading the operations of Par Pharmaceutical. Tony brings experience and expertise that will be tremendously valuable in effectively managing our U.S. generics business. They are both seasoned and trusted executives who consistently deliver results and I have tremendous confidence in their ability to help drive operational excellence and growth for Endo.”
Coughlin, who began his career at Wyckoff Chemical Co. in 1988, was most recently VP operations at Par Pharmaceutical Cos., a position he moved into after Endo acquired Par in September 2015. He was Par’s COO before the acquisition, and before joining par Coughlin held various leadership roles with Glenmark Generics USA and its parent company Glenmark Generics, including president and CEO of Glenmark Generics USA/Glenmark Generics. Before his role at the helm of Glenmark, he oversaw the company’s North America, Western European and Eastern European generics businesses, as well as its global active pharmaceutical ingredient business and Indian generics operations. Before Glenmark, he was SVP at Dr. Reddy’s Laboratories.
"I am excited and honored to take on this role and look forward to partnering with Paul and our talented senior leadership team as we look to deliver on our goals, including focusing on operational excellence as well as developing and delivering products for patients in need,” Coughlin said.
Pera was most recently Par’s chief commercial officer, joining the company in February 2014 as part of Par’s acquisition of JHP Pharmaceutical, where he held a similar position. As chief commercial officer he oversaw sales, marketing, pricing and customer operations functions. Before JHP, Pera was SVP scupply chain management for AmerisourceBergen for about five years. He is currently the secretary-treasurer for the Generic Pharmaceutical Association’s board of directors.
"This is an important time for the U.S. generics industry, Par and Endo and I am excited to take on this role. I am looking forward to continuing to work closely with Paul and even more collaboratively with the broader Endo Executive Leadership Team to execute and drive success for our Company and to deliver the highest quality, accessible products to the patients we serve," said Mr. Pera.